| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 1997;64:363-367
© 1997 The Society of Thoracic Surgeons
Department of Surgery II and Institute of Ecological Sciences, University of Occupational and Environmental Health, School of Medicine, Kitakyushu, Japan
Accepted for publication March 10, 1997.
Background. This study was designed to evaluate the incidence and clinical implications of detection of micrometastatic cancer cells in bone marrow aspirates of patients with operable non–small cell lung cancer. The relationship between micrometastatic cells and p53 overexpression in the primary tumor was also assessed.
Methods. Thirty-nine patients with stages I through III non–small cell lung cancer who underwent curative resection were entered into this study. Immunohistochemistry with monoclonal antibody to cytokeratin 18 was used to detect tumor cells in bone marrow. Immunostaining of p53 protein in the corresponding primary tumors was also done.
Results. Cytokeratin 18–positive cells were detected in 15 (39%) of the 39 patients. Overexpression of p53 was associated with positivity of the tumor cells in the bone marrow at borderline significance (14/29 versus 1/10; p = 0.0574). The patients with cytokeratin 18–positive cells in bone marrow demonstrated a significantly earlier recurrence than those without such cells (p = 0.0083, log-rank test).
Conclusions. Micrometastatic cancer cells were frequently present in bone marrow of patients with operable non–small cell lung cancer and may be a significant predictor of early recurrence. Further evaluation of this method may be useful in identifying patients with non–small cell lung cancer who are most likely to benefit from adjuvant chemotherapy.
This article has been cited by other articles:
|
|
 |
|
  G. A. Silvestri, M. K. Gould, M. L. Margolis, L. T. Tanoue, D. McCrory, E. Toloza, and F. Detterbeck Noninvasive Staging of Non-small Cell Lung Cancer: ACCP Evidenced-Based Clinical Practice Guidelines (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 178S - 201S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Sienel, I. Mecklenburg, S. Dango, P. Ehrhardt, A. Kirschbaum, B. Passlick, and K. Pantel Detection of MAGE-A Transcripts in Bone Marrow Is an Independent Prognostic Factor in Operable Non-Small-Cell Lung Cancer Clin. Cancer Res., July 1, 2007; 13(13): 3840 - 3847. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Park, C.-T. Lee, H. W. Lee, H. J. Baek, J. I. Zo, and Y. M. Shim Postoperative adjuvant chemotherapy for stage I non-small cell lung cancer Eur. J. Cardiothorac. Surg., June 1, 2005; 27(6): 1086 - 1091. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Yasumoto, T. Osaki, Y. Watanabe, H. Kato, and T. Yoshimura Prognostic value of cytokeratin-positive cells in the bone marrow and lymph nodes of patients with resected nonsmall cell lung cancer: a multicenter prospective study Ann. Thorac. Surg., July 1, 2003; 76(1): 194 - 201. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. G. Lugo, S. Braun, R. J. Cote, K. Pantel, and V. Rusch Detection and Measurement of Occult Disease for the Prognosis of Solid Tumors J. Clin. Oncol., July 1, 2003; 21(13): 2609 - 2615. [Full Text] [PDF]
|
|
|
|
|
|
X. Jiao and M. J. Krasna Clinical significance of micrometastasis in lung and esophageal cancer: a new paradigm in thoracic oncology Ann. Thorac. Surg., July 1, 2002; 74(1): 278 - 284. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Osaki, T. Oyama, C.-D. Gu, T. Yamashita, T. So, M. Takenoyama, K. Sugio, and K. Yasumoto Prognostic Impact of Micrometastatic Tumor Cells in the Lymph Nodes and Bone Marrow of Patients With Completely Resected Stage I Non-Small-Cell Lung Cancer J. Clin. Oncol., July 1, 2002; 20(13): 2930 - 2936. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Passlick, B. Kubuschock, W. Sienel, O. Thetter, K. Pantel, and J.R. Izbicki Mediastinal lymphadenectomy in non-small cell lung cancer: effectiveness in patients with or without nodal micrometastases -- results of a preliminary study Eur. J. Cardiothorac. Surg., March 1, 2002; 21(3): 520 - 526. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Ahrendt, S. C. Yang, L. Wu, C. M. Roig, P. Russell, W. H. Westra, J. Jen, M. V. Brock, R. F. Heitmiller, and D. Sidransky Molecular assessment of lymph nodes in patients with resected stage I non-small cell lung cancer: Preliminary results of a prospective study J. Thorac. Cardiovasc. Surg., March 1, 2002; 123(3): 466 - 474. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.J. Poncelet, B. Weynand, F. Ferdin, A.R. Robert, and P.H. Noirhomme Bone marrow micrometastasis might not be a short-term predictor of survival in early stages non-small cell lung carcinoma Eur. J. Cardiothorac. Surg., September 1, 2001; 20(3): 481 - 488. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. C. Mineo, V. Ambrogi, V. Corsaro, and M. Roselli Postoperative adjuvant therapy for stage IB non-small-cell lung cancer Eur. J. Cardiothorac. Surg., August 1, 2001; 20(2): 378 - 384. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. F. Patz Jr., J. Connolly, and J. Herndon Prognostic Value of Thoracic FDG PET Imaging After Treatment for Non-Small Cell Lung Cancer Am. J. Roentgenol., March 1, 2000; 174(3): 769 - 774. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Passlick, B. Kubuschok, J. R. Izbicki, O. Thetter, and K. Pantel Isolated tumor cells in bone marrow predict reduced survival in node-negative non-small cell lung cancer Ann. Thorac. Surg., December 1, 1999; 68(6): 2053 - 2058. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Monzo, R. Rosell, E. Felip, J. Astudillo, J. J. Sanchez, J. Maestre, C. Martin, A. Font, A. Barnadas, and A. Abad A Novel Anti-Apoptosis Gene: Re-expression of Survivin Messenger RNA as a Prognosis Marker in Non-Small-Cell Lung Cancers J. Clin. Oncol., July 1, 1999; 17(7): 2100 - 2100. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Yoshino, R. Nakanishi, T. Osaki, M. Takenoyama, S. Taga, T. Hanagiri, and K. Yasumoto Unfavorable Prognosis of Patients With Stage II Non-small Cell Lung Cancer Associated With Macroscopic Nodal Metastases Chest, July 1, 1999; 116(1): 144 - 149. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. I. Garver, G. L. Zorn, X. Wu, D. C. McGiffin, K. R. Young, and N. B. Pinkard Recurrence of Bronchioloalveolar Carcinoma in Transplanted Lungs N. Engl. J. Med., April 8, 1999; 340(14): 1071 - 1074. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Wada, R. Miyahara, F. Tanaka, and S. Hitomi Postoperative adjuvant chemotherapy with PVM (Cisplatin+Vindesine+Mitomycin C) and UFT (Uracil+Tegaful) in resected stage I-II NSCLC (non-small cell lung cancer): a randomized clinical trial Eur. J. Cardiothorac. Surg., April 1, 1999; 15(4): 438 - 443. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ohgami, T. Tsuda, T. Osaki, T. Mitsudomi, Y. Morimoto, T. Higashi, and K. Yasumoto MUC1 mucin mRNA expression in stage I lung adenocarcinoma and its association with early recurrence Ann. Thorac. Surg., March 1, 1999; 67(3): 810 - 814. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
